Latest News

Date Title Topic
07 Jun 2017 Three Biosimilar Medicines with Rituximab as Active Substance Received a Positive Opinion from EMA Haematologic malignancies
06 Jun 2017 NICE Issues Quality Standard for Haematological Cancers Haematologic malignancies
ESMO Election: 2020-2021
02 Jun 2017 A Need to Harmonise the Prescribing Information for Etoposide in the EU Anticancer agents & Biologic therapy
01 Jun 2017 ESMO 2017 Media Alert: Integrating Science Into Oncology for a Better Patient Outcome
01 Jun 2017 FDA Accepts for Priority Review Application for Nivolumab in Previously Treated Hepatocellular Carcinoma Gastrointestinal cancers - Cancer Immunology and Immunotherapy
31 May 2017 Press Release: ESMO Welcomes the Adoption of the 2017 WHO Cancer Resolution Bioethics, legal and economic issues
31 May 2017 FDA Broadens Ceritinib Indication to Previously Untreated ALK-positive Metastatic NSCLC Personalised medicine - Lung and other thoracic tumours - Anticancer agents & Biologic therapy
30 May 2017 NICE Terminates Technology Appraisal for Afatinib in Advanced Squamous NSCLC After Platinum-based Chemotherapy Lung and other thoracic tumours - Anticancer agents & Biologic therapy
29 May 2017 FDA Grants Accelerated Approval to Pembrolizumab for Unresectable or Metastatic MSI-H or dMMR Solid Tumours Cancer Immunology and Immunotherapy
26 May 2017 Withdrawal of the Marketing Authorisation Application for Vosaroxin Haematologic malignancies - Anticancer agents & Biologic therapy
Track Chairs' Top Picks
24 May 2017 EMA Completes an Arbitration Procedure for Dexrazoxane Palliative and supportive care
22 May 2017 EMA Adopts a Negative Opinion for Anamorelin Hydrochloride Palliative and supportive care - Lung and other thoracic tumours
22 May 2017 EMA Adopts a New Indication for Ceritinib Lung and other thoracic tumours - Anticancer agents & Biologic therapy